Urilax Special Precautions

EC tablet: Potential risk of syncope, intraoperative floppy iris syndrome, patient with serious or life-threatening allergy with sulfa drugs. Monitor BP closely on patient receiving antihypertensive drugs. Rule out carcinoma of the prostate prior to treatment with tamsulosin.
ER tablet: Although less likely to occur compared with other selective alpha-1 blockers, reduction in blood pressure, orthostatic hypotension or even syncope may rarely occur during treatment with tamsulosin. At the first sign of orthostatic hypotension which may include dizziness or weakness, the patient should be instructed to sit or lie down until the symptoms abate. At the initiation of therapy, patients should therefore be advised to avoid situations where injury could possibly be sustained in the event that syncope would occur. Occasional cases of priapism have been observed with tamsulosin like with other selective alpha-1 blockers where patients should be advised on its proper and urgent treatment to prevent the possible consequence of permanent impotence. Other conditions which may manifest similarly as benign prostatic hyperplasia especially prostatic cancer should be excluded prior to initiation of therapy with tamsulosin. Digital rectal examination and, when necessary, determination of prostate specific antigen (PSA) should be performed before treatment and at regular intervals thereafter. The Intraoperative Floppy Iris Syndrome (IFIS), a variant of the Small Pupil Syndrome has been observed during cataract surgery in some patients currently or previously treated with tamsulosin. IFIS may lead to increased procedural complications during the operation and therefore the initiation of therapy with tamsulosin in patients in whom cataract surgery is being contemplated is not recommended. Discontinuation of tamsulosin therapy 1-2 weeks prior to cataract surgery have been considered beneficial, however concrete evidence of such benefit and the time of discontinuation of therapy prior to cataract surgery has not yet been established. As part of the pre-operative assessment, current or previous therapy with tamsulosin should be ascertained prior to cataract surgery so appropriate measures can be put in place to manage IFIS during surgery. Caution should be exercised when administering tamsulosin to patients with severe renal insufficiency (endogenous creatinine clearance of less than 10 mL/min) as the clinical and pharmacokinetic profile of tamsulosin in these patients have not been fully studied. Although changes in the plasma concentration of the unbound active drug is minimal or none at all, caution should still be exercised when tamsulosin is administered in patients with severe hepatic insufficiency and the elderly since there is a definite though minimal decrease in the clearance of tamsulosin in these patients.
Tamsulosin is not intended to be used in women or children.